Modality
mAb
MOA
HPK1i
Target
PD-1
Pathway
RAS/MAPK
ACCGBM
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
Feb 2021
→ Jun 2028
Phase 1Current
NCT07756717
1,542 pts·ACC
2021-02→2028-06·Not yet recruiting
1,542 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-04-132w awayEMA Filing· ACC
2026-12-269mo awayConference· ACC
2028-06-142.2y awayPh2 Data· ACC
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1/2
Not yet…
Catalysts
EMA Filing
2026-04-13 · 2w away
ACC
Conference
2026-12-26 · 9mo away
ACC
Ph2 Data
2028-06-14 · 2.2y away
ACC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07756717 | Phase 1/2 | ACC | Not yet recr... | 1542 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 |